Humacyte

Humacyte Humacyte produces life-sustaining, human bioengineered blood vessels and tissues designed to remodel with the patient's own cells.

🚨 Join the SVS Women’s Section for an exclusive educational webinar on AV access in women.Humacyte will present the comp...
08/31/2026

🚨 Join the SVS Women’s Section for an exclusive educational webinar on AV access in women.

Humacyte will present the complete 12-month interim analysis from the CLN-PRO-V012 study, a multicenter, randomized Phase 3 trial evaluating the acellular tissue-engineered vessel (ATEV) compared with autogenous arteriovenous fistula (AVF) for hemodialysis vascular access in women with end-stage kidney disease.

Women have historically experienced lower rates of AVF maturation, greater catheter dependence, and higher rates of vascular access complications than men—yet prospective randomized studies specifically designed to address this unmet need have been limited. This one-hour webinar will review efficacy and safety outcomes, clinical interpretation of the findings, and potential implications for future vascular access strategies in women at increased risk of AVF maturation failure.

REGISTER NOW: 🔗 https://vascular.org/vascular-specialists/education-and-meetings/meetings/interim-analysis-results-pivotal-randomized

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

🚨 A significant milestone for the advancement of vascular access care.Results from Humacyte’s Phase 3 V007 trial have be...
08/20/2026

🚨 A significant milestone for the advancement of vascular access care.

Results from Humacyte’s Phase 3 V007 trial have been published in The Lancet Digital Health, providing peer-reviewed validation of positive findings showing the superiority of the ATEV over autogenous arteriovenous fistula (AVF) for hemodialysis vascular access after one year of follow-up. These data demonstrate the potential of the ATEV to help address an important unmet need in hemodialysis access for patients at higher risk of fistula failure, particularly for all female patients and male patients with obesity and diabetes. The publication complements Humacyte’s positive Phase 3 V012 data in women on dialysis, further strengthening the growing body of evidence supporting the investigational use of the ATEV in AV Access.

For more details, read the full press release here: 🔗 https://bit.ly/4wzRZUQ

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an
investigational product and has not been approved for sale by the FDA or any other regulatory
agency.

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

🚨 Symvess® acellular tissue engineered vessel-tyod reaches a new commercial milestone in Arizona.Humacyte is pleased to ...
08/18/2026

🚨 Symvess® acellular tissue engineered vessel-tyod reaches a new commercial milestone in Arizona.

Humacyte is pleased to announce that Jeromy Brink, MD, a board-certified vascular and endovascular surgeon in Phoenix, performed the first post-BLA approval Symvess implants in Arizona.

This milestone reflects continued market adoption of Symvess as hospitals and surgeons add an important on-demand treatment option for appropriate vascular injury patients.

After gaining access to the first-in-class product, Dr. Brink has already performed four Symvess implants in Phoenix, AZ and described Symvess as the “most revolutionary advancement in open surgical bypass in 30 years.”

Symvess is the first and only FDA-approved bioengineered human vessel and is available off the shelf in the operating room for adults with extremity arterial injury when autologous vein graft is not feasible.

For more details, read the full press release here: 🔗bit.ly/4zq5GrQ

Learn more about Humacyte at www.humacyte.com

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

A major milestone for Humacyte and the future of cardiovascular care!The FDA has accepted our IND application for the fi...
07/29/2026

A major milestone for Humacyte and the future of cardiovascular care!

The FDA has accepted our IND application for the first-in-human clinical study of the Coronary Tissue Engineered Vessel (CTEV) in coronary artery bypass grafting (CABG). CTEV is a first-in-class, universally implantable bioengineered human blood vessel produced using the same platform as Humacyte's FDA-approved acellular tissue engineered vessel (ATEV) and is designed to be available off-the-shelf, eliminating the need to harvest a patient's own vessel for bypass surgery.

This important regulatory milestone brings us one step closer to evaluating a potential new treatment option for patients undergoing one of the most common cardiovascular procedures performed today.

Phase 2a study initiation is expected this quarter.

For more details read the full press release here: 🔗 https://bit.ly/4x7D6d3

The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

$HUMA

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

07/28/2026

Come See Us!

The Humacyte team will be at leading vascular and surgical meetings across North America, sharing the science behind Symvess and offering hands-on opportunities to handle, cut, and suture the vessel.

From exhibit booths to simulation stations and symposium sessions, each meeting offers an opportunity to connect with our team, ask questions, and explore how Symvess may help in extremity arterial injury when autologous vein graft is not feasible.

We look forward to connecting with you at the following meetings:

Alabama Vascular Society
Braselton, GA | Jul 30 – Aug 1
• Experience our Simulation Station
• Join us for our Breakfast Symposium with Miguel Manzur, MD — Friday, July 31 at 7:00 AM, Elan Ballroom D

Virginia Vascular Society Annual Meeting
Irvington, VA | Sep 11 – 13

AAST 85th Annual Meeting & Clinical Congress
Dallas, TX | Sep 16 – 19

Eastern Vascular Society Annual Meeting
Washington, DC | Sep 17 – 19
• Experience our Simulation Station
• Join us for a Technology Forum presentation

Midwestern Vascular Society 50th Annual Meeting
Chicago, IL | Sep 17 – 20
• Visit our Hands-On Station at the Technology & Technique Vascular Simulation Program on Thursday, September 17

Georgia Vascular Society Scientific Sessions
Greensboro, GA | Sep 18 – 20

Western Vascular Society Annual Meeting
British Columbia, CA | Sep 26 – 29
• Join us for a Lunch Symposium on Monday, September 28

Stop by, connect with our team, and see Symvess in action.

Learn more here: www.symvess.com.

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life-threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000357

Vascular Society
Vascular Society
Vascular Surgical Society
Association for the Surgery of Trauma
Vascular Society
Vascular Society
Vascular Society

$HUMA

07/03/2026

Celebrating 250 Years of American Independence and Innovation!

This Independence Day carries special meaning as our nation celebrates its 250th anniversary—a milestone honoring the vision and ingenuity that have shaped the United States for generations.

Progress through our country’s history has been driven by individuals willing to pursue bold ideas, solve complex challenges, and invest in a healthier, stronger future. At Humacyte, we are proud to contribute to that tradition by advancing innovations designed to improve patient care and expand possibilities in regenerative medicine.

From all of us at Humacyte, we wish you a happy and safe 4th of July.

Learn more about our innovations at www.humacyte.com

Humacyte is a trademark and property of Humacyte Global, Inc.
© 2026 Humacyte Global Inc. All Rights Reserved.

As Men's Health Month comes to a close, it's a reminder that taking care of your health isn't just about today—it's abou...
06/30/2026

As Men's Health Month comes to a close, it's a reminder that taking care of your health isn't just about today—it's about being there for the people and moments that matter most.

The support of family and loved ones can make a meaningful difference in building healthy habits, staying active, and supporting long-term vascular health.¹

Caring for your health today can help you stay engaged in life's milestones tomorrow—from family celebrations and summer adventures to everyday moments spent with those you love.

Talk with your healthcare provider about your vascular health, stay active, and lean on your support network as you work toward a healthier future.

At Humacyte, we support efforts to raise awareness of vascular health and encourage men to have conversations with their healthcare providers about their health.

Learn more about Humacyte's commitment to advancing innovation in vascular medicine at Humacyte.com

References:
1. American Heart Association. How Is PAD Treated? Updated April 27, 2026.

Humacyte is a registered trademark and is property of Humacyte Global, Inc.
© 2026 Humacyte Global Inc. All Rights Reserved.

Men's Health Month is a reminder that small steps can make a lasting difference.Many cardiovascular risk factors, includ...
06/26/2026

Men's Health Month is a reminder that small steps can make a lasting difference.

Many cardiovascular risk factors, including blood pressure, cholesterol, and activity level, are controllable with support from your healthcare provider.1

Staying active, monitoring blood pressure and cholesterol, and maintaining strong connections with family, friends, and healthcare providers can all contribute to better cardiovascular health over time. Peer support from people with shared experiences can also encourage healthier behaviors and help individuals stay engaged in lifestyle changes.2

At Humacyte, we support awareness of cardiovascular health and the importance of proactive care. Learn more at www.Humacyte.com.

References:
1. Wadhera RK, et al. Cardiovascular Statistics in the United States, 2026. J Am Coll Cardiol. 2026
2. Sharp P, et al. Men’s peer support for mental health challenges. Health Promot Int. 2024.

Humacyte is a trademark and property of Humacyte Global, Inc.
© 2026 Humacyte Global Inc. All Rights Reserved.

We hope you had the opportunity to connect with our team and learn more about Symvess® acellular tissue engineered vesse...
06/18/2026

We hope you had the opportunity to connect with our team and learn more about Symvess® acellular tissue engineered vessel-tyod at the TOUCHPOINT Hands-on / SIM Lab, The Women in Vascular Surgery Forum, or our exhibit booth at the VAM 2026 conference. We truly appreciate the engagement and interest in Symvess—our first-in-class, universally implantable, bioengineered human vessel indicated for urgent extremity arterial injury.

We are excited to continue supporting you and your teams in learning more about this innovative repair option, and we sincerely value the thoughtful questions and discussions.

VAM 2026 offered so many valuable educational opportunities. Contact us to keep the discussion going. We look forward to connecting soon!

Contact Us Here: https://symvess.com/contact-us/

Learn more about Symvess here: https://bit.ly/atev_prod_huma

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000349

$HUMA

🚨 New Clinical Milestone from Humacyte in AV Access!Humacyte recently announced interim Phase 3 (V012) results in female...
06/16/2026

🚨 New Clinical Milestone from Humacyte in AV Access!

Humacyte recently announced interim Phase 3 (V012) results in female dialysis access patients. The ATEV met V012’s primary endpoint and showed superior catheter-free days (p=0.00070) compared with autologous arteriovenous fistula (AVF), the current standard of care. Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received an AVF.

The data reinforce the potential to improve outcomes in a patient population with a high unmet need.

This major milestone marks the end of the Phase 3 study enrollment and will support Humacyte’s plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026.

Full results were presented June 11 at the Society for Vascular Surgery Annual Meeting in Boston during the Women’s Health Seminar.

For more details, read the full press release here: 🔗 https://bit.ly/3SaQzSc

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

Address

2525 NC-54
Durham, NC

Telephone

+19193139633

Website

Alerts

Be the first to know and let us send you an email when Humacyte posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Humacyte:

Shortcuts

Share

Category